Mckesson
McKesson Corporation, a leading player in the healthcare industry, is headquartered in California and operates extensively across North America. Founded in 1833, McKesson has evolved into a vital partner for healthcare providers, offering a comprehensive range of services including pharmaceutical distribution, healthcare management solutions, and technology integration. The company is renowned for its innovative approach to supply chain management and its commitment to improving patient care through advanced data analytics and pharmacy services. With a strong market position, McKesson consistently ranks among the top companies in the Fortune 500, reflecting its significant impact on the healthcare landscape. Its dedication to enhancing operational efficiency and patient outcomes sets McKesson apart as a trusted leader in the industry.
DitchCarbon Score
How does Mckesson's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mckesson's score of 49 is higher than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mckesson's reported carbon emissions
In 2024, McKesson Corporation reported significant carbon emissions, totalling approximately 79,848,000 kg CO2e for Scope 1, 152,129,000 kg CO2e for Scope 2 (market-based), and a staggering 32,569,160,000 kg CO2e for Scope 3 emissions. This reflects a comprehensive approach to emissions reporting, covering all three scopes, with Scope 3 emissions primarily driven by purchased goods and services, which accounted for about 31,925,992,000 kg CO2e. McKesson has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 50.4% by FY2032, using FY2020 as the baseline year. This target is aligned with the Science Based Targets initiative (SBTi) and is designed to support the global goal of limiting temperature rise to 1.5°C. Additionally, McKesson plans for 70% of its suppliers, by spend, to have science-based targets by FY2027, further extending its climate impact beyond its direct operations. The company has shown a commitment to transparency and accountability in its emissions reporting, with a clear focus on reducing its carbon footprint in the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 92,194,000 | 00,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 188,912,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 28,733,000 | 00,000,000 | 00,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mckesson is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
